Calliditas Therapeutics
Emelie Bäckvall has a diverse work experience spanning multiple industries. Emelie most recently worked as an HR Manager at Calliditas Therapeutics AB starting in 2022. Prior to that, they served as an HR Manager at HMSHost International from 2018 to 2022, overseeing both operational and strategic HR activities in Sweden. Additionally, Emelie worked as an HR Officer at Esprit in 2018, where they provided HR support and managed HR administration tasks in the Nordics.
Earlier in their career, Emelie held the position of HR Manager and Head of Operations at Centrala Partihallen AB from 2011 to 2018. In this role, they were responsible for the operational and strategic aspects of HR, as well as overall operations. Emelie also worked as an HR Business Partner at Centrala Partihallen AB from 2005 to 2011, focusing on developing and implementing HR processes and handling personnel-related issues.
Furthermore, Emelie has experience as a Key Account Manager at Centrala Partihallen AB from 2004 to 2009, where they built relationships with customers and partners and met their needs through collaboration.
Emelie's career began at Bauhaus in 2001 as a Kassabiträde.
Emelie Bäckvall completed their education at two different institutions. From 2001 to 2004, they attended Stockholms Hotell och Restaurang skola, where they did not pursue a specific degree or field of study. Later, in 2012 to 2013, they studied at FEI Företagsekonomiska Institutet, where they obtained the degree of Diplomerad Personalvetare/HR chef. No information is provided regarding the field of study during this period.
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.